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Introduction
Coronary vasomotor tone has been recognized to
play a crucial role in determinating the ischaemic
threshold and the occurrence of spontaneous as well
as exercise-induced myocardial ischaemia. The tra-
ditional concept of the 'rigid tube' has been changed
during the past 15 years and the coronary arteries
are considered today to represent a 'dynamic tube'.
Changes in coronary artery dimensions are caused
through the contraction and relaxation of the smooth
musculature within the vessel wall. Vasoactive sub-
stances released from the endothelium play a crucial
role in the regulation of vessel size and coronary
vasomotor tone. The endothelium is the largest and
most active paracrine organ in the body, producing
potent vasoactive, procoagulant, fibrinolytic, and
anticoagulant substances. Thus, a diseased coronary
endothelium may have a dramatic effect on the func-
tion of the vessels and may cause or contribute to the
occurrence of myocardial ischaemia under high de-
mand situations, such as physical exercise or mental
stress. An important variable in this regulation is
coronary blood flow.
whereas a-adrenergic blockade has been shown to
reduce attacks of variant angina and to abolish
coronary vasoconstriction. However, an increase in
/?-adrenergic tone has been associated with coronary
artery vasodilation'21.
Coronary vasomotion is an important deter-
minant of myocardial perfusion, not only in normals
but also in patients with angina pectoris'3'. Distur-
bances in vasomotion are closely linked to the
development of atherosclerosis and play an integral
part in the pathophysiology of myocardial ischae-
mia'41. In patients with angina pectoris, there is a
circadian variation in ischaemic events, being most
frequent in the morning hours'51. This is due to the
enhanced release of epinephrine and norepine-
phrine'61, which results in an increase in heart rate and
blood pressure as well as enhanced platelet aggrega-
bility[7]. Accordingly, vascular resistance has been
shown to be increased and ischaemic threshold to
be reduced in the morning hours'81. This enhanced
release of catecholamines leads to coronary vaso-
constriction and transient reductions in coronary
blood flow with a spontaneous decrease in anginal
threshold, a condition referred to as 'mixed angina'191.
Pathophysiologic determinants of
coronary vasomotion
Regional coronary blood flow is dependent on
several factors such as perfusion pressure, metabolic
demands, coronary resistance and vasomotor tone1'1.
Coronary vasomotor tone is the result of vaso-
constricting and vasodilating stimuli originating from
the autonomic nervous system, hormones and vessel
(wall-derived) vasoactive substances. Several studies
have shown the presence of both a- and /?-adrenergic
receptors in animal and human coronary arteries. An
increase in a-adrenergic tone has been associated with
the occurrence of coronary artery vasoconstriction,
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Role of the endothelium
The endothelium modulates coronary vasomotion by
the uptake, storage, and metabolism of numerous
substances'10"121, such as serotonin, norepinephrine,
bradykinin, acetylcholine etc. (Fig. 1). Paracrine-
released substances (autacoids) such as the
endothelium-derived relaxing factor (EDRF), prosta-
cyclin (PG12), platelet activating factor, and endo-
thelin are synthesized and released from the endo-
thelium for vascular control and haemodynamic
homeostasis. Nitric oxide has been recognized to
be EDRF, although some of the pharmacological
actions of EDRF cannot be explained by nitric oxide
solely. Nitric oxide is continuously synthesized and
released, both without stimulation (basal nitric oxide
release) and with stimulation (stimulated release)
elicited by local and circulating agonists (such as
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Figure 1 Determinants of coronary vasomotor tone. In an intact endothelium, various stimulatory
compounds elicit NO-mediated dilation or vasoconstriction. ACE=angiotensin converting enzyme;
Ach=acetylcholine; ADP=adenosine diphosphate; Bk = bradykinin; cAMP/cGMP=cyclic adenosine/
guanidine monophosphate; ECE=endothelin converting enzyme; EDHF=endothelial derived hyperpolarizing
factor; ET-l=endothelin-l; 5HT=5-hydroxytryptamine (serotonin); L-arg=L-arginine; NO = nitric oxide;
PGH2=prostaglandin H2; PGl2=prostacyclin 12; TGF/?=tranforming growth factor /?,; Thr=thrombin;
TXA2=thrombozane A2. Circles represent receptors (AT = angiotensinergic; B = bradykininergic;
M = muscarinergic; P = purinergic; T=thrombin receptor). (Reproduced with permission from Liischer TF and
Noll G. The endothelium in coronary vascular control. In: Heart disease — Update 3. Philadelphia: W. B.
Saunders Company, 1995: 2).
bradykinin, serotonin, norepinephrine) or, most
importantly by viscous drug-induced shear stress
from the perfusing blood (resulting in flow-dependent
dilation). The pulsatile stretching of the endothelium
adds to this mechanically stimulated nitric oxide
release'13!. Furthermore, all vasoactive compounds
and drugs modulate endothelial nitric oxide synthesis
and release in either a receptor-dependent or in a
flow-dependent (=shear stress-mediated) manner'14'.
Under physiological conditions, the continuous dila-
tor action of endothelial autacoids compensates for
the continuous constrictor effect of norepinephrine
released from the nerve endings'15'. In patients with
impaired endothelial function flow-dependent, nitric
oxide-mediated dilator responses are diminished'16'
and at the same time the myogenic constrictor
responses are enhanced resulting in an enhanced
autoregulatory response'171.
Previous studies on coronary vasomotor tone
in humans used conventional coronary angiography
for measuring changes in response to various phar-
macological stimuli'18"20'. Recently, Schachinger and
Zeiher'4' combined angiographic measurements and
intracoronary ultrasound for calculation of vaso-
motor tone. They used the ratio of a change in
circumference divided by the total vasomotor range
as a measure of vasomotor tone. However, pressure
as an important determinant of vascular tone was
neglected in this model'41.
Vasomotion in coronary artery disease
Normal vessels
A number of pharmacological agents such as sero-
tonin, norepinephrine, vasopressin, papaverine, but
mainly acetylcholine have been used to study the
vasomotor response of coronary arteries'21"24'. In
clinical studies, intracoronary acetylcholine has been
shown to constrict coronary arteries in the presence
of atherosclerotic lesions, whereas it dilates normal
coronary arteries'25'. Constriction during static but
dilation during dynamic exercise has been reported
previously'3'. A heterogeneous response of angio-
graphically smooth vessels has been described.
Undetected atherosclerosis in angiographically nor-
mal vessels of patients with coronary artery disease
may account for insufficient vasodilator response due
to endothelial dysfunction. Progressive impairment of
endothelial function has been reported with different
stages of coronary atherosclerosis in patients with
angiographically smooth coronary arteries'16'. Thus,
a functional disorder of the 'normal' coronary
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Figure 2 Normal vessels (open squares) show exercise-
induced dilation which is further enhanced after sublingual
nitroglycerin (Nitro si). In contrast, stenoses show
exercise-induced vasoconstriction, which is reversed after
sublingual nitroglycerin. delta-Ex, percent change of
cross-sectional area.
arteries may account for the abnormal response of
various physiological and pharmacological stimuli in
patients with coronary artery disease.
Stenosis
The observation that stenotic arteries can change
its diameter depends on the fact that approximately
70% of all stenotic lesions are eccentric and have
a normal musculo-elastic wall segment within the
stenosis'3'26'271. Intracoronary acetylcholine induces
vasoconstriction of stenotic coronary arteries. In con-
trast to the normal coronary arteries, constriction of
stenotic vessels has been reported during static'281 and
dynamic exercise'3'29'301 (Fig. 2). The mechanism of
coronary stenosis narrowing during exercise or after
intracoronary acetylcholine is not clear but might be
explained by either:
(1) endothelial dysfunction with insufficient produc-
tion of EDRF
(2) an increase in circulating catecholamines during
exercise'31"33'
(3) platelet aggregation with release of the vaso-
constricting compounds serotonin and thrombo-
xane A2
(4) a passive collapse of the free vessel wall when
coronary flow velocity increases during exercise
(Bernoulli mechanism)'34' and/or
(5) a reduction of coronary blood flow increase dur-
ing exercise due to tachycardia with a decrease in
diastolic perfusion time'301'
Cardiovascular risk factors and
coronary vasomotion
Hyper cholesterolaemia
There has been increasing interest in the literature
on the functional impact of hypercholesterolaemia
on coronary vascular function ' ' . Impairment of
endothelium-dependent vasodilation in angiographi-
cally normal coronary arteries has been reported in
the presence of hypercholesterolaemia'16'37'381. This
has been attributed to a dysfunction of the endo-
thelium via an attenuation of EDRF release by
oxidised low-density lipoproteins (LDL)'39'401 and/or
stimulation of endothelin-mRNA as well as the
release of endothelin'4'1. Lerman and co-workers'42'
showed that hypercholesterolaemia elevates plasma
endothelin concentration and enhances coronary
artery tissue endothelin immunoreactivity, which is
thought to be responsible for abnormal endothelial
function. These changes play an important role in the
development of early atherosclerotic lesions, which
is characterized by functional alterations of the
endothelial cell before morphological changes are
detectable. Hypercholesterolaemia impairs exercise-
induced coronary vasodilation in angiographically
normal coronary arteries: as total serum cholesterol
increases exercise-induced dilation is diminished. In
humans, an inverse correlation between total or LDL
cholesterol and exercise-induced vasodilation in
angiographically normal coronary arteries has been
reported by Seiler et a/.'43' (Fig. 3). An increase in
serum cholesterol above 200 mg. 100ml"1 reduces
exercise-induced vasodilation to 12%, whereas in the
presence of a normal serum cholesterol vasodilation
amounts to 20%. When serum cholesterol is increased
above 250 mg . 100 ml" ' coronary vasomotion is
abolished (+4% vasodilation during exercise, P=ns).
However, no influence of serum cholesterol was
observed in stenotic vessels. Similar observations
have been made in children with familiar hyper-
lipidaemia'441 and in porcine coronary arteries with
diet-induced hypercholesterolaemia'45'.
The effect of hypercholesterolaemia on human
vascular function has been evaluated by Creager et al.
in the forearm of patients with normal and those
with elevated serum cholesterol. The forearm vessels
were chosen for investigation since they almost
never show atherosclerotic changes'46'. There was
a diminished flow increase to methacholine in
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Figure 3 An inverse correlation is found between total serum cholesterol and
exercise-induced vasomotion of angiographically normal but not of stenotic cor-
onary artery segments. Choi=total serum cholesterol; delta-Ex=percent change of
cross-sectional luminal area. Solid symbols=normal serum cholesterol; open
symbols=elevated serum cholesterol.
hypercholesterolaemic patients compared to normal
subjects. They concluded that hypercholesterolaemia
in the absence of atherosclerosis is associated with
abnormal function of the vascular endothelium.
Thus, abnormal coronary vasomotion in patients
with hypercholesterolaemia143'471 may not necessarily
be associated with overt atherosclerosis. Thus, two-
different mechanisms of hypercholesterolaemia in the
pathophysiology of coronary artery disease must be
postulated: (1) a direct (toxic?) effect of oxidized
LDL-cholesterol on the endothelium (functional dis-
order) and (2) a chronic effect inducing structural
changes of the vessel wall.
Hypertension
High blood pressure has a direct effect on the arteries
which is characterized by structural changes of the
vessel wall such as media hypertrophy, increase in
endothelial cell volume, microvascular rarefication,
and augmentation of the extracellular matrix'48"511.
These changes may lead to impaired endothelium-
dependent relaxation'52'531. In hypertensive patients
with angiographically documented coronary artery
disease, Frielingsdorf et al. found a markedly blunted
vasodilatory response of non-stenotic vessels com-
pared with normotensive control subjects'541 (Fig. 4).
Furthermore, reduced coronary vasodilation of nor-
mal coronary arteries was found in response to exer-
cise, whereas endothelium-independent vasodilation
to nitroglycerin was maintained in hypertensive
patients. This suggests a preserved function of the
vascular smooth musculature but a primary defect of
the 'normal' epicardial coronary arteries in hyperten-
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Figure 4 Luminal area change during exercise of normal
and stenotic coronary arteries in hypertensive patients
(•) and normotensive control subjects (D) with coronary
artery disease. Values are mean ± SEM.
sive patients with coronary artery disease. Alterations
of endothelial function are probably a consequence
rather than a cause of high blood pressure, and hence
the degree of endothelial dysfunction and its mechan-
ism change with increasing severity and duration of
hypertension. In animal models with antihypertensive
treatment, reductions of blood pressure are able to
reverse endothelial dysfunction'55'561, although the
exact mechanism is not fully understood.
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Figure 5 There is a significant, inverse correlation be-
tween the number of cardiovascular risk factors (horizon-
tal axis) and mean exercise-induced percent change in
coronary luminal area (delta-ex, %; vertical axis).
O=mean delta-ex (%).
Other coronary risk factors
Although hypercholesterolaemia and hypertension
have been identified as major risk factors for
endothelial dysfunction, several additional coronary
risk factors are known to be responsible for
impaired coronary vasomotion. Long-term cigarette
smoking has been found to be associated with
impaired endothelium-dependent coronary vaso-
dilation regardless of the presence or absence of
coronary atherosclerotic lesions'571. A significant
inverse correlation has been reported between the
mean exercise-induced vasomotor response and the
number of coronary risk factors'43', such as hyper-
cholesterolaemia, hypertension, family history, obes-
ity and smoking, indicating that the accumulation of
different risk factors show an additive (adverse) effect
(Fig. 5)
cells'581. An accelerated form of this process can be
induced by a denuding, deep endothelial injury as
it often occurs during percutaneous transluminal
coronary angioplasty, in patients undergoing cor-
onary bypass grafting, or by an immune injury such
as in patients undergoing heart transplantation'591.
A direct relationship between left ventricular
muscle mass and coronary dimensions has been
reported in experimental animals and clinical
studies'60"661. As a regulatory mechanism for this
increase in vessel dimensions, blood flow velocity has
been postulated. An increase in mean flow velocity
has been associated with a change in shear stress,
which has been shown to be a mediator for the release
of EDRF, i.e. nitric oxide. In low and moderate
grades of left ventricular hypertrophy, an appropriate
increase in coronary artery size was reported, whereas
in severe left ventricular hypertrophy an inappro-
priate growth of the coronary arteries with a reduc-
tion in cross-sectional vessel area per 100 g muscle
mass was described in primary'671 as well as in
secondary'67'681 left ventricular hypertrophy. In severe
hypertrophy the coronary arteries seem to be too
small for the increase in left ventricular muscle mass
as a result of inadequate growth of the coronary
arteries. Furthermore, impaired vasodilator capacity
of the epicardial coronary arteries in patients with
secondary left ventricular hypertrophy has been
reported previously'691. This has been attributed to
an increase in resting flow. Although the size of the
coronary arteries is not a limiting factor for myo-
cardial perfusion, functional adaptation via the
release of EDRF seems to be inadequate in severe
hypertrophy. Insufficient growth of the coronary
arteries has been observed in severe left ventricular
hypertrophy'701 and, thus, may explain the occurrence
of myocardial ischaemia under high demand situ-
ations such as exercise. The exact control mechanism
of the coronary growth is not completely understood,
but may involve several factors, such as structural
(vascular remodelling) and functional (endothelial
dysfunction) changes'671.
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Vascular remodelling
The basis for the development of atherosclerosis is
damage to the arterial endothelium with accumu-
lation of lipids, adhesion of monocytes, and platelet
aggregation. Release of various growth factors leads
to the migration and proliferation of smooth muscle
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